Biogen MS deal with Acorda could be worth over $500 million
A day after reporting a failure in the clinic with a mid-stage multiple sclerosis compound, Biogen Idec has responded by buying certain rights to Acorda Therapeutics’ investigational MS drug Fampridine-SR

Read more ...